Hansa Medical AB applies for listing on Nasdaq Stockholm
Hansa Medical AB applies for listing of its shares on the main market of Nasdaq Stockholm.Hansa Medical AB’s share is publicly traded on NASDAQ First North since October 17, 2007.Hansa Medical AB has submitted a preliminary application have its shares listed on the main market of Nasdaq Stockholm. About IdeSIdeS, a unique molecule with a novel mechanism, is a bacterial enzyme that cleaves human IgG antibodies. IdeS degrades all IgG specifically, swiftly and efficiently. IdeS has been tested for safety and efficacy in numerous in vitro and in vivo models. During 2013, a Phase I